Considering intractable uncertainties and the wicked nature of many sustainability challenges, there is a need to both forecast assess potential for improvements in with new ventures. While it tempting think forecasting terms ‘predicting outcomes’, such an interpretation assumes causal logic, failing acknowledge effectuation processes often at work sustainability-focused innovative entrepreneur...

The adoptive transfer of recombinant-methionyl human interleukin 2 (rIL-2)-activated autologous peripheral blood mononuclear lymphokine-activated killer (LAK) cells to cancer patients is being evaluated as an alternative to conventional cancer therapy. We have independently developed an alternative regimen to previously reported adoptive immunotherapy protocols using rIL-2 and LAK cells which f...

Gray leaf spot (GLS) caused by Cercospora zeae-maydis or zeina is one of the devastating maize foliar diseases worldwide. Identification GLS-resistant quantitative trait loci (QTL)/genes plays an urgent role in improving GLS resistance breeding practice. Two groups recombinant inbred line (RIL) populations derived from CML373 × Ye107 and Chang7-2 were generated subjected to genotyping-by-sequen...

Shouichi Fujimoto, MD, First Department of Internal Medicine, Miyazaki Medical College 5200, Kihara, Kiyotake, Miyazaki 889-16 (Japan) Table 1. Time course change of UProE, UFR and UProE/UCreE following intravenous injection of rIL-2 at a dose of 70 × 104 JRU (mean ± SE, n = 8) Dear Sir, Interleukin-2 (IL-2) is a lymphokine modulating T cell function. Recombinant human IL-2 (rIL-2) has been use...

The effects of hematopoietic growth factors on in vitro human megakaryocytopoiesis were studied using a serum-depleted culture system. Both recombinant interleukin-3 (r-IL-3) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) increased megakaryocyte (MK) colony formation (P less than .01) above that observed in baseline cultures. Recombinant interleukin-4 (rIL-4) and int...

Administration in vivo of recombinant interleukin 2 (rIL-2) to mice induces a polyclonal IgM response. When co-administered with a specific antigen, rIL-2 can enhance concentrations of murine IgM antibodies specific for the antigen by fivefold within 7 d of initial treatment. IgM antibodies that are induced after injection of rIL-2 include antibodies specific for J5, a cell wall core lipopolysa...